These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8032650

  • 1. Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.
    McAuliffe SJ, Moors JA, Jones HB.
    Br J Pharmacol; 1994 May; 112(1):272-6. PubMed ID: 8032650
    [Abstract] [Full Text] [Related]

  • 2. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD, Müller TH.
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [Abstract] [Full Text] [Related]

  • 3. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 4. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 5. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 11. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengård C, Hedner U, Saldeen TG.
    J Am Coll Cardiol; 1995 Mar 01; 25(3):753-60. PubMed ID: 7860925
    [Abstract] [Full Text] [Related]

  • 12. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ.
    J Pharmacol Exp Ther; 1988 Aug 01; 246(2):790-6. PubMed ID: 3136245
    [Abstract] [Full Text] [Related]

  • 13. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
    Vandeplassche G, Hermans C, Van Dael L, Wouters L, De Clerck F.
    J Cardiovasc Pharmacol; 1993 Jan 01; 21(1):56-69. PubMed ID: 7678680
    [Abstract] [Full Text] [Related]

  • 14. Redirection of arachidonic acid metabolism by ICI D1542: effects on thrombus formation in the coronary artery of the anaesthetized dog.
    McAuliffe SJ, Moors JA, Snow HM, Wayne M, Jessup R.
    Br J Pharmacol; 1993 Apr 01; 108(4):901-6. PubMed ID: 8485629
    [Abstract] [Full Text] [Related]

  • 15. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP, Brownrigg NJ, Butcher HM, Garcia R, Jessup R, Lee VJ, Tunstall S, Wayne MG.
    Br J Pharmacol; 1993 Dec 01; 110(4):1600-6. PubMed ID: 8306107
    [Abstract] [Full Text] [Related]

  • 16. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY, Nichols WW, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1996 Feb 01; 27(2):283-9. PubMed ID: 8720429
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ.
    Thromb Res; 2005 Feb 01; 116(6):519-24. PubMed ID: 16181987
    [Abstract] [Full Text] [Related]

  • 18. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 01; 23(2):194-202. PubMed ID: 7511747
    [Abstract] [Full Text] [Related]

  • 19. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 01; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 20. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 01; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.